Compare Stocks: BRTX, NEUP, ALLR, and QNTM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLR Allarity Therapeutics	$1.42	$1.29	$0.77 ▼ $2.35	$22.59M	0.51	78,913 shs	111,510 shs
BRTX Biorestorative Therapies	$0.22	$0.31	$0.16 ▼ $1.89	$5.49M	0.79	370,668 shs	75,803 shs
NEUP Neuphoria Therapeutics	$3.91	$3.86	$3.19 ▼ $21.40	$21.11M	0.75	65,398 shs	179,816 shs
QNTM Quantum Biopharma	$3.44	$3.38	$2.07 ▼ $21.00	$22.02M	0.45	297,051 shs	137,564 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLR Allarity Therapeutics	0.00%	+3.65%	+19.33%	-19.77%	+50.33%
BRTX Biorestorative Therapies	0.00%	-4.69%	-25.76%	+3.51%	-85.93%
NEUP Neuphoria Therapeutics	0.00%	+1.03%	+7.42%	-28.65%	-45.54%
QNTM Quantum Biopharma	0.00%	-9.47%	+15.05%	-62.77%	-80.97%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLR Allarity Therapeutics	$1.42	$1.29	$0.77 ▼ $2.35	$22.59M	0.51	78,913 shs	111,510 shs
BRTX Biorestorative Therapies	$0.22	$0.31	$0.16 ▼ $1.89	$5.49M	0.79	370,668 shs	75,803 shs
NEUP Neuphoria Therapeutics	$3.91	$3.86	$3.19 ▼ $21.40	$21.11M	0.75	65,398 shs	179,816 shs
QNTM Quantum Biopharma	$3.44	$3.38	$2.07 ▼ $21.00	$22.02M	0.45	297,051 shs	137,564 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLR Allarity Therapeutics	0.00%	+3.65%	+19.33%	-19.77%	+50.33%
BRTX Biorestorative Therapies	0.00%	-4.69%	-25.76%	+3.51%	-85.93%
NEUP Neuphoria Therapeutics	0.00%	+1.03%	+7.42%	-28.65%	-45.54%
QNTM Quantum Biopharma	0.00%	-9.47%	+15.05%	-62.77%	-80.97%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLR Allarity Therapeutics	2.00	Hold	$10.25	621.83% Upside
BRTX Biorestorative Therapies	1.00	Sell	N/A	N/A
NEUP Neuphoria Therapeutics	2.00	Hold	$21.00	437.08% Upside
QNTM Quantum Biopharma	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest BRTX, NEUP, ALLR, and QNTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	QNTM Quantum Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	ALLR Allarity Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/8/2026	ALLR Allarity Therapeutics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$9.75 ➝ $10.25
6/1/2026	NEUP Neuphoria Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
5/28/2026	QNTM Quantum Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/27/2026	BRTX Biorestorative Therapies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 8/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLR Allarity Therapeutics	$320K	70.60	N/A	N/A	$0.61 per share	2.33
BRTX Biorestorative Therapies	$357.87K	15.33	N/A	N/A	$0.04 per share	5.38
NEUP Neuphoria Therapeutics	$15.65M	1.35	$0.16 per share	25.09	$10.11 per share	0.39
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	$1.34 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLR Allarity Therapeutics	-$11.23M	-$0.78	N/A	N/A	N/A	N/A	-152.77%	-46.50%	N/A
BRTX Biorestorative Therapies	-$14.24M	-$1.07	N/A	N/A	N/A	-3,088.27%	-508.42%	-230.94%	8/25/2026 (Estimated)
NEUP Neuphoria Therapeutics	-$370K	-$11.06	N/A	N/A	N/A	N/A	-76.93%	-54.76%	9/2/2026 (Estimated)
QNTM Quantum Biopharma	-$26.17M	-$5.49	N/A	N/A	N/A	N/A	-582.23%	-184.20%	11/6/2026 (Estimated)

Latest BRTX, NEUP, ALLR, and QNTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2026	Q4 2026	NEUP Neuphoria Therapeutics	-$0.56	N/A	N/A	N/A	N/A	N/A
8/25/2026	Q2 2026	BRTX Biorestorative Therapies	-$0.10	N/A	N/A	N/A	$0.60 million	N/A
8/14/2026	Q2 2026	ALLR Allarity Therapeutics	-$0.25	-$0.21	+$0.04	-$0.21	N/A	N/A
8/13/2026	Q2 2026	QNTM Quantum Biopharma	-$0.4116	-$0.47	-$0.0584	-$0.47	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	N/A
BRTX Biorestorative Therapies	N/A	N/A	N/A	N/A	N/A
NEUP Neuphoria Therapeutics	N/A	N/A	N/A	N/A	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLR Allarity Therapeutics	N/A	1.11	1.11
BRTX Biorestorative Therapies	N/A	2.35	2.35
NEUP Neuphoria Therapeutics	N/A	14.31	14.31
QNTM Quantum Biopharma	N/A	1.20	1.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLR Allarity Therapeutics	11.53%
BRTX Biorestorative Therapies	69.38%
NEUP Neuphoria Therapeutics	15.90%
QNTM Quantum Biopharma	1.24%

Insider Ownership

Company	Insider Ownership
ALLR Allarity Therapeutics	0.16%
BRTX Biorestorative Therapies	13.60%
NEUP Neuphoria Therapeutics	1.50%
QNTM Quantum Biopharma	8.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLR Allarity Therapeutics	10	15.91 million	15.89 million	Not Optionable
BRTX Biorestorative Therapies	7	25.48 million	22.01 million	Not Optionable
NEUP Neuphoria Therapeutics	N/A	5.40 million	5.32 million	N/A
QNTM Quantum Biopharma	N/A	6.40 million	5.85 million	N/A

BRTX, NEUP, ALLR, and QNTM Headlines

Recent News About These Companies

Quantum Biopharma Provides Corporate Update

August 21 at 7:00 PM | globenewswire.com

Quantum BioPharma (QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves

August 20, 2026 | finance.yahoo.com

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves

August 20, 2026 | markets.businessinsider.com

Quantum BioPharma (QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2

August 17, 2026 | finance.yahoo.com

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2

August 17, 2026 | usatoday.com

Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial

August 14, 2026 | globenewswire.com

Quantum BioPharma (QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis

August 13, 2026 | finance.yahoo.com

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis

August 13, 2026 | markets.businessinsider.com

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS Into Phase 2 Multiple Sclerosis Trial

August 11, 2026 | theglobeandmail.com

Quantum BioPharma (QNTM) Receives FDA Clearance to Advance Lucid-MS Into Phase 2

August 10, 2026 | finance.yahoo.com

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances MS Imaging Study with Encouraging Preliminary Results

August 3, 2026 | markets.businessinsider.com

Quantum BioPharma (QNTM) Advances MS Imaging Study With Encouraging Preliminary Results

August 3, 2026 | finance.yahoo.com

Quantum BioPharma Announces Closing of Debt Settlement

July 29, 2026 | globenewswire.com

Quantum BioPharma (QNTM) Executive Outlines Lucid-MS Development Strategy and Commercial Growth Plans

July 29, 2026 | finance.yahoo.com

Quantum BioPharma (QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions

July 22, 2026 | finance.yahoo.com

Quantum BioPharma Announces Intention to Settle Debt

July 20, 2026 | globenewswire.com

Quantum BioPharma (QNTM) Expands Clinical Development of Neuroprotective Therapy

July 15, 2026 | finance.yahoo.com

Why Quantum BioPharma (QNTM) Is 'One to Watch'

July 10, 2026 | finance.yahoo.com

Quantum BioPharma Provides Corporate Update

July 7, 2026 | globenewswire.com

Quantum BioPharma (QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast

July 2, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRTX, NEUP, ALLR, and QNTM Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

$1.42 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Biorestorative Therapies NASDAQ:BRTX

$0.22 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

Neuphoria Therapeutics NASDAQ:NEUP

$3.91 0.00 (0.00%)

As of 08/21/2026 03:59 PM Eastern

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Quantum Biopharma NASDAQ:QNTM

$3.44 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BRTX, NEUP, ALLR, and QNTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BRTX, NEUP, ALLR, and QNTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BRTX, NEUP, ALLR, and QNTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRTX, NEUP, ALLR, and QNTM Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

Biorestorative Therapies NASDAQ:BRTX

Neuphoria Therapeutics NASDAQ:NEUP

Quantum Biopharma NASDAQ:QNTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BRTX, NEUP, ALLR, and QNTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BRTX, NEUP, ALLR, and QNTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BRTX, NEUP, ALLR, and QNTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRTX, NEUP, ALLR, and QNTM Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

Biorestorative Therapies NASDAQ:BRTX

Neuphoria Therapeutics NASDAQ:NEUP

Quantum Biopharma NASDAQ:QNTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools